Compare Summit Therapeutics Inc (SMMT) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Yum China Holdings Inc — how do they compare? Summit Therapeutics Inc trades at $14.58 (market cap $10.48B), while Yum China Holdings Inc trades at $43.48 (market cap $15.09B). The key difference: Yum China Holdings Inc is the larger of the two by market cap, and Yum China Holdings Inc pays a 2.64% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | YUMC | |
|---|---|---|
Market Cap | $10.48B | $15.09B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.32 | $57.95 |
52-Week Low | $13.05 | $40.18 |
Enterprise Value | $9.90B | $15.98B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
YUMC trades at $42.77, down 2.51% today, with a bullish technical outlook supported by moving averages despite overbought RSI readings. The company shows consistent revenue growth, reaching $11.80B in 2025, and has beaten earnings estimates in three consecutive quarters. Recent strategic moves include the acquisition of Pizza Hut China, enhancing local control and cost synergies. Analyst sentiment remains strongly positive with 14 buy ratings and no sell recommendations.
The outlook for YUMC is favorable due to solid fundamentals and strategic initiatives, though risks include macroeconomic headwinds in China and competitive pressures. Valuation metrics like a P/E of 16.83 and EV/EBITDA of 8.76 suggest reasonable pricing relative to earnings, supporting potential upside if execution continues to exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
